Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Uremic toxin accumulation is a significant factor leading to increased complications and mortality in dialysis patients, with gut microbiota dysbiosis playing a key role. This study aims to evaluate the effects of Fecal Microbiota Transplantation (FMT) on uremic toxin levels, micro-inflammatory status, and clinical symptoms in maintenance hemodialysis patients, providing new strategies for improving their prognosis.
A double-blind, randomized, placebo-controlled trial was conducted across three hemodialysis centers from June 2021 to June 2023. 120 maintenance hemodialysis patients (>3 months) were enrolled and randomly assigned to the FMT group (n=60) or the placebo group (n=60). The FMT group received healthy donor microbiota transplantation via colonoscopy (30g frozen fecal microbiota preparation), while the placebo group received an equivalent amount of normal saline. All patients were assessed at baseline, 4 weeks, and 12 weeks post-intervention for the following: 1. Primary outcomes: serum levels of p-cresyl sulfate (PCS) and indoxyl sulfate (IS); 2. Secondary outcomes: inflammatory markers (IL-6, TNF-α), gut microbiota diversity (16S rRNA sequencing), uremic symptom score (UDSA scale); 3. Safety: incidence of adverse events. Data were analyzed using repeated measures ANOVA, t-tests, and microbiome analysis.
1、Toxin Clearance: At 12 weeks, the FMT group showed reductions in PCS and IS levels by 43.2% and 38.7%, respectively (both P<0.001), significantly superior to the placebo group (reduction <5%).
2、Microbiota Improvement: The gut microbiota α-diversity index increased by 2.1-fold (P=0.002) in the FMT group, and the abundance of short-chain fatty acid-producing bacteria (e.g., Faecalibacterium) increased by 3.5-fold.
3、Inflammation Alleviation: IL-6 and TNF-α levels decreased by 52.3% and 47.8%, respectively (both P<0.01), showing a significant positive correlation with the reduction in toxin levels (r=0.68).
4、Symptom Improvement: Skin pruritus (response rate 76.7%) and loss of appetite (improvement rate 68.3%) were significantly alleviated, with the total UDSA score decreasing by 41.5 points (P<0.001).
5、Safety: There was no statistically significant difference in serious adverse events between the two groups (P>0.05). The incidence of transient diarrhea in the FMT group was 13.3%.
Fecal microbiota transplantation effectively reconstructs gut microecological balance in dialysis patients. By increasing the abundance and function of beneficial bacteria, it significantly reduces uremic toxin accumulation and micro-inflammatory status, with a favorable safety profile. This study provides high-level evidence-based support for gut-kidney axis intervention in dialysis patients. Clinical application is recommended under strict donor screening conditions, and future research should explore standardized microbiota preparations and optimal intervention frequency.
